Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic and Oncology Target Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ENOPH1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ENOPH1 WT & Mutant Recombinant Protein, high purity (>95%), Endotoxin <1EU/ug, Sequence Verified. | View ENOPH1 Products |
| Homology Control (ENOPH2) | ENOPH2 (RPCL1) recombinant protein for selectivity counter-screening, Sequence Verified. | View ENOPH2 Products |
| Gene Delivery | ENOPH1 Promise-ORF Lentivirus, full-length ORF for stable cell lines. | View ENOPH1 Products |
| Benchmark Ab | Anti-ENOPH1 (Rabbit Monoclonal) – research grade positive control for Western/IP/IHC. | View ENOPH1 Products |
| Validator | ENOPH1 siRNA Set for knockdown verification and phenotypic assays. | View ENOPH1 Products |
| Related Target A | MTAP – synergistic target in methionine salvage pathway; synthetic lethality partner. | View MTAP Products |
| Related Target B | MAT2A – upstream methionine adenosyltransferase; metabolic node. | View MAT2A Products |
| Related Target C | AMD1 – upstream polyamine synthesis regulator. | View AMD1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Assay Reproducibility | High purity (>95%) E. coli / HEK293 expressed proteins (endotoxin <1EU/ug) |
| Confirming Specificity | Sequence Verified targets to ensure exact structural match |
| Lack of Controls | Recombinant Benchmark Antibodies included for assay validation |
| False Positives in Screening | Validated siRNA included for cellular specificity checks |
| Homology Selectivity (vs ENOPH2) | Human ENOPH1 & ENOPH2 proteins available as ortholog pair; >95% purity; for off-target liability screening |
| Enzymatic Activity Validation | WT protein with intact enolase/phosphatase domains; available in activity-compatible buffer |
| Disease Model Validation | Deafness-associated mutants (e.g., p.Gly195Glu) available as purified proteins |
| Cellular Target Engagement | Validated siRNA included for specificity controls in cellular assays |
Live ENOPH1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials
- Latest Metabolic Research
- Latest Resistance Research
- Recent Patent Filings
Global Clinical Landscape & Future Outlook
The understanding of ENOPH1's role in the methionine salvage pathway is expanding beyond rare genetic disorders (DFNB76 deafness, CORD19 optic neuropathy) into oncology metabolic dependencies. The race for targeting metabolic vulnerabilities in cancer is intensifying, with researchers focusing on synthetic lethality paradigms – specifically combining ENOPH1 inhibition with other metabolic stressors (e.g., MTAP deletion). While still early in clinical translation, ENOPH1 represents a promising target for small molecule inhibitors, PROTACs, and gene therapy approaches. Future R&D will see expansion into combination therapies and biomarker-linked development.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Academic / Early Biotech | MTAP-deleted Cancers, Solid Tumors (Metabolic) | Enzymatic selectivity; need high-purity active WT protein |
| PROTAC / Degrader | Emerging Biotech | Oncology (broad) | Cellular validation; need lentivirus & siRNA for target engagement confirmation |
| Gene Therapy / siRNA | Academia & Gene Therapy Specialists | DFNB76 Deafness, CORD19 Optic Neuropathy, Neuro/Metabolic Disorders | Mutant protein rescue assays; need disease-variant proteins and stable cell lines |